We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

479 hedge funds and large institutions have $27.5B invested in Vertex Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 194 increasing their positions, 155 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 47

25% more repeat investments, than reductions

Existing positions increased: 194 | Existing positions reduced: 155

1% more funds holding

Funds holding: 474 → 479 (+5)

1% more capital invested

Capital invested by funds: $27.3B → $27.5B (+$279M)

17% less call options, than puts

Call options by funds: $80.4M | Put options by funds: $97.3M

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
479
Holders Change
+5
Holders Change %
+1.05%
% of All Funds
12.77%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
62
Increased
194
Reduced
155
Closed
47
Calls
$80.4M
Puts
$97.3M
Net Calls
-$16.9M
Net Calls Change
+$182M

Top Buyers

1
MCM
Marsico Capital Management
Colorado
+$259M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
+$222M
3
UBS AM
UBS AM
Illinois
+$157M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$121M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$113M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$238M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$220M
3
O
OrbiMed
New York
-$191M
4
Capital World Investors
Capital World Investors
California
-$139M
5
Millennium Management
Millennium Management
New York
-$79.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAA
26
Managed Account Advisors
New Jersey
$223M +$57.2M +477,522 +34%
Goldman Sachs
27
Goldman Sachs
New York
$209M -$11.8M -98,221 -5%
Viking Global Investors
28
Viking Global Investors
Connecticut
$209M +$121M +1,005,950 +132%
Norges Bank
29
Norges Bank
Norway
$188M -$1.81M -15,131 -0.9%
Adage Capital Partners
30
Adage Capital Partners
Massachusetts
$169M -$79.6M -664,548 -32%
BB
31
BB Biotech
Switzerland
$157M -$2.4M -20,000 -1%
Wells Fargo
32
Wells Fargo
California
$153M -$44.1M -367,769 -22%
TCIM
33
TIAA CREF Investment Management
New York
$142M +$25.9M +216,514 +22%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$132M +$12.8M +106,572 +11%
Deutsche Bank
35
Deutsche Bank
Germany
$131M -$8.11M -67,699 -6%
BlackRock
36
BlackRock
New York
$113M +$9.78M +81,587 +9%
Franklin Resources
37
Franklin Resources
California
$112M -$1.48M -12,329 -1%
Legal & General Group
38
Legal & General Group
United Kingdom
$108M -$184K -1,536 -0.2%
Thrivent Financial for Lutherans
39
Thrivent Financial for Lutherans
Minnesota
$108M -$33.1M -276,091 -23%
AQR Capital Management
40
AQR Capital Management
Connecticut
$106M +$33M +275,353 +44%
First Trust Advisors
41
First Trust Advisors
Illinois
$100M -$19.8M -165,610 -16%
AAMU
42
Amundi Asset Management US
Massachusetts
$93.7M +$17.6M +146,990 +23%
CS
43
Credit Suisse
Switzerland
$90.3M -$2.12M -17,688 -2%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$88.4M – – –
JHIU
45
Janus Henderson Investors US
Colorado
$85.7M +$29.6M +246,796 +51%
Allianz Asset Management
46
Allianz Asset Management
Germany
$82.7M -$2.65M -22,111 -3%
American Century Companies
47
American Century Companies
Missouri
$78.8M +$66M +550,634 +468%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$77.6M +$416K +3,475 +0.5%
HCM
49
Hoplite Capital Management
New York
$74.9M +$3.43M +28,650 +5%
Sumitomo Mitsui Trust Group
50
Sumitomo Mitsui Trust Group
Japan
$72.3M +$8.09M +67,558 +12%
1
2
3 4 5

VRTX Hedge Fund Activity: Q1 2015 in Review

479 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2015, worth a combined $27.5B — up 1% from $27.3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new VRTX positions and 47 closed out — a net gain of 15 holders — while 194 added to existing stakes and 155 trimmed.

The largest buyer was Marsico Capital Management, opening a new position worth an estimated $259M. The largest seller was Vanguard Group, cutting an estimated $238M.

  • 479 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2015, up from 474 in Q4 2014.
  • Funds reported $27.5B of Vertex Pharmaceuticals stock for Q1 2015, up 1% quarter-over-quarter.
  • 62 funds opened new Vertex Pharmaceuticals positions in Q1 2015 and 47 closed out, a net change of +15 holders.
  • The largest Vertex Pharmaceuticals buyer in Q1 2015 was Marsico Capital Management, an estimated $259M added.
  • The largest Vertex Pharmaceuticals seller in Q1 2015 was Vanguard Group, an estimated $238M sold.

Based on aggregated 13F filings for Q1 2015.